Identification of new fucosyltransferase-8 inhibitors: An integrated biochemical, biophysical, and computational approach
5 affiliations
- 1Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center of Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan
- 2H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan
- 3Institute of Molecular Biology and Biochemistry, The University of Lahore, Lahore, Pakistan
- 4National Facility for Coastal & Marine Research (NFCMR) & Centre for Ocean Research (COR), Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India
- 5Institute of Drug Discovery Technology, Ningbo University, Ningbo, Zhejiang, China
Abstract
The α-1,6-fucosyltransferase (FUT8) mediated core fucosylation is responsible for several pathophysiological processes, including prostate cancer progression. FUT8 is a promising therapeutic target owing to its effects on cell migration and its capacity to convert androgen-dependent prostate cancer cells into androgen-independent cells. This study, therefore, investigates potential FUT8 inhibitors as therapeutic options for prostate cancer by targeting FUT8-mediated core fucosylation using in vitro, biophysical, and computational approaches. Eight of the 265 compounds showed significant cytotoxicity against the prostate cancer (PC3) cell line in in vitro screening. These compounds demonstrated dose-dependent reductions in cell viability, with IC50 values ranging from 2.94 ± 0.04 to 75.82 ± 2.10 µM. These compounds were non-cytotoxic against the normal human fibroblast (BJ) cell line. Biophysical and in silico analyses were conducted on active compounds to obtain atomic-level structural details of interactions between FUT8 and ligands. Among these, compounds 1, 3, 6, and 7 showed significant Saturation Transfer Difference Nuclear Magnetic Resonance (STD-NMR) effects and induced a decrease in the melting temperature (Tm) of FUT8 in the differential scanning fluorimetry (DSF) assay (0.25°C–9°C), indicating ligand-associated destabilization of the protein. Molecular docking and molecular dynamics simulation results showed that compounds 1, 2, 3, 4, 6, and 7 stably interacted with the FUT8 binding site. These compounds also exhibited anti-migratory activity in a scratch cell assay, as indicated by scratch closure of only 3.14% to 14.18%, compared with 45.45% to 100% in the control group. Our study identified compounds 1, 3, 6, and 7 as promising leads against the FUT8 enzyme. Further mechanistic and in vivo studies are required to evaluate their mechanisms of action for FUT8-driven prostate cancer progression.
Related
- Abiotic stress sensing in plants: Biochemical and biophysical basis
- Carbothioamide functionalized paroxetine analogues as antiparasitic agents targeting the hypoxanthine-guanine-xanthine phosphoribosyltransferase enzyme: Synthesis, characterization, biochemical, biophysical, and in silico studies
- Identification of potential donors for bruchid (Callosobruchus maculatus) resistance in blackgram through multi-environments phenotyping and biochemical profiling
- Computational identification of responding T cell clones from longitudinal repertoire sequencing
- Identification of Cysteine-Reactive Early Mitotic Inhibitors
BibTeX
@article{awais2026identification,
title = {{Identification of new fucosyltransferase-8 inhibitors: An integrated biochemical, biophysical, and computational approach}},
author = {Muhammad Awais and Noor Rahman and Sumaira Javaid and Atia-tul- Wahab and Thirugnanasambandam Rajendran and M. Iqbal Choudhary and Humaira Zafar},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0349302},
url = {https://doi.org/10.1371/journal.pone.0349302},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Identification of new fucosyltransferase-8 inhibitors: An integrated biochemical, biophysical, and computational approach
AU - Muhammad Awais
AU - Noor Rahman
AU - Sumaira Javaid
AU - Atia-tul- Wahab
AU - Thirugnanasambandam Rajendran
AU - M. Iqbal Choudhary
AU - Humaira Zafar
PY - 2026
DA - 2026/10/05
JO - PLOS One
DO - 10.1371/journal.pone.0349302
UR - https://doi.org/10.1371/journal.pone.0349302
AB - The α-1,6-fucosyltransferase (FUT8) mediated core fucosylation is responsible for several pathophysiological processes, including prostate cancer progression. FUT8 is a promising therapeutic target owing to its effects on cell migration and its capacity to convert androgen-dependent prostate cancer cells into androgen-independent cells. This study, therefore, investigates potential FUT8 inhibitors as therapeutic options for prostate cancer by targeting FUT8-mediated core fucosylation using in vitro, biophysical, and computational approaches. Eight of the 265 compounds showed significant cytotoxicity against the prostate cancer (PC3) cell line in in vitro screening. These compounds demonstrated dose-dependent reductions in cell viability, with IC50 values ranging from 2.94 ± 0.04 to 75.82 ± 2.10 µM. These compounds were non-cytotoxic against the normal human fibroblast (BJ) cell line. Biophysical and in silico analyses were conducted on active compounds to obtain atomic-level structural details of interactions between FUT8 and ligands. Among these, compounds 1, 3, 6, and 7 showed significant Saturation Transfer Difference Nuclear Magnetic Resonance (STD-NMR) effects and induced a decrease in the melting temperature (Tm) of FUT8 in the differential scanning fluorimetry (DSF) assay (0.25°C–9°C), indicating ligand-associated destabilization of the protein. Molecular docking and molecular dynamics simulation results showed that compounds 1, 2, 3, 4, 6, and 7 stably interacted with the FUT8 binding site. These compounds also exhibited anti-migratory activity in a scratch cell assay, as indicated by scratch closure of only 3.14% to 14.18%, compared with 45.45% to 100% in the control group. Our study identified compounds 1, 3, 6, and 7 as promising leads against the FUT8 enzyme. Further mechanistic and in vivo studies are required to evaluate their mechanisms of action for FUT8-driven prostate cancer progression.
SN - 1932-6203
ER -